Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

2
Abeona Therapeutics (ABEO) Reports Q2 Loss, Lags Revenue Estimates

2018-08-10 zacks
Abeona Therapeutics (ABEO - Free Report) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items.
GD UNIT ABEO ABEOW

1
ABEO / Abeona Therapeutics Inc. FORM 8-K (Current Report)

2018-08-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
ABEO

1
Abeona Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights

2018-08-09 globenewswire
NEW YORK and CLEVELAND, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced financial results for the second quarter of 2018. The Company will host a call to update investors on recent clinical developments and quarter financial results on Friday, August 10th at 10:00 am (Eastern).
ABEO ABEOW

1
ABEO / Abeona Therapeutics Inc. FORM 10-Q (Quarterly Report)

2018-08-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
ABEO

126
Biotech Movers and Shakers for Aug. 6

2018-08-06 biospace
Cellectis – France-based Cellectis named Novartis veteran Stefan Scherto as its new head of clinical development and deputy medical officer. Prior to his role at Cellectis, Scherto served as head of early development of strategy and innovation in U.S. oncology for Novartis. Scherto is expected to play a key role in moving Cellectis’ off-the-shelf gene-edited CAR-T cell product candidates toward commercialization.
ABT ALXN GILD TRVN QSII KITE ABEO ABEOW ABT BCART

1
ABEO / Abeona Therapeutics Inc. FORM 8-K (Current Report)

2018-07-30 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
ABEO

10
Biotech Movers and Shakers for July 30

2018-07-30 biospace
Nabriva Therapeutics – Nabriva Therapeutics restructured part of its leadership team in the wake of the acquisition of Zavante Therapeutics. Colin Broom, who had served as chief executive officer of Nabriva, was replaced by Zavante CEO Ted Schroeder. Broom will maintain a seat on the board of directors and serve in an advisory role to Schroeder. Steven Gelone, Nabriva's chief scientific officer and head of business & corporate development, has been named president and chief operating officer of Nabriva.
VYGR OPTI ALXN NBRV ABEO ABEOW ARIA OPBXF

2
Fibrocell Science: An Underappreciated Gene Therapy Play

2018-07-27 seekingalpha
There are clear risks in terms of continued dilution, but we believe these risks are outweighed by the positive data presented from Fibrocell's lead gene therapy program, FCX-007.
FCSC KRYS ABEO ABEOW

32
Rounds Report: Nephros Posts Strong Preliminary Financial Results For Q2

2018-07-13 seekingalpha
The overall bioscience market traded with a mixed sentiment for the day. Nevertheless, many equities under over coverage continued to rally.
NTLA SLDB SGMO CRSP ABEO XBI ONCE RGNX NEPH EDIT ADVM IBB ABEOW

2
Synacor Sees Hammer Chart Pattern: Time to Buy?

2018-07-12 zacks
Synacor, Inc. (SYNC - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because SYNC recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
LMT SYNC ABEO ABEOW

1
Old Dominion Freight Line Sees Hammer Chart Pattern: Time to Buy?

2018-07-12 zacks
Old Dominion Freight Line, Inc. (ODFL - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because ODFL recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
ODFL LMT ABEO ABEOW ODLF

4
GMS Sees Hammer Chart Pattern: Time to Buy?

2018-07-12 zacks
GMS Inc. (GMS - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because GMS recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
LMT ABEO ABEOW GMS

3
Pacific Ethanol Sees Hammer Chart Pattern: Time to Buy?

2018-07-12 zacks
Pacific Ethanol, Inc. (PEIX - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because PEIX recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
LMT PEIX ABEO ABEOW

1
Implied Volatility Surging for Abeona Therapeutics (ABEO) Stock Options

2018-07-11 zacks
Investors in Abeona Therapeutics Inc. (ABEO - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $17.50 Call had some of the highest implied volatility of all equity options today.
ABEO ABEOW

1
ABEO / Abeona Therapeutics Inc. null

2018-07-07 sec.gov
June 5, 2018 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street NE Washington, DC 20549 Attention: Ada S
ABEO

ABEO: Abeona Therapeutics Analysis and Research Report

2018-05-14 - Asif

OVERVIEW Abeona Therapeutics Inc. is a Delaware corporation. Abeona Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. The company's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona Therapeutics is also developing ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition Abeona Therapeutics is developing a proprietary vector platform, ...

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 00289Y107